Stronger Tumor Control
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
A single protein may be holding back CAR T cancer therapy
A single protein may be holding back CAR T cancer therapy - Date: - June 2, 2026 - Source: - University Hospital Tübingen - Summary: - A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time. When NFIL3 was disabled, the cells remained stronger for longer and controlled tumors more effectively in animal models.
Nanoparticles boost delivery of lung cancer drugs 30-fold
Nanoparticles boost delivery of lung cancer drugs 30-fold Lisa Lock Scientific Editor Robert Egan Associate Editor Lung cancer remains one of the world's deadliest cancers, yet despite decades of effort to develop new drugs, many fail because they don't stay in the body long enough to be effective or because they damage healthy organs. Now, Adelaide University researchers have developed a novel nanoparticle "delivery vehicle" that precisely targets cancer drugs to the lungs while helping to...
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.